Opinion (revised) on Cancer risk to consumers from Creosote containing less than 50 ppm benzo-[a]-pyrene and/or from wood treated with such Creosote and estimation of respective magnitude expressed at the 8th CSTEE plenary meeting, Brussels, 4 March 1999.
1.
Introduction
2. Dermal
Carcinogenicity Study of Two
Coal Tar Products
(CTP)
3. An
Evaluation of the
Carcinogenicity of Coal-Tar
Derived Creosote
4.
Foundation of the Appeal
against the EC-directive on
Creosote
5. Study
on the Justification in
Scientific Terms of Allowing
the Netherlands to retain its
National Laws on Creosote in
Place of Council Directive
94/60/EEC
6.
Position of the Government of
the Federal Republic of
Germany
7.
Karlehagen Epidemiology
Study
8.
Evaluation of German Exposure
Estimates by ERM
(Environmental Resource
Management, London)
9. Human
Health and Environmental
Concerns of Creosote
10. Report
to the Commission of the
European Union by SORGO
consultant
11. Study
on the Justification in
Scientific Terms of Allowing
Sweden to retain its National
Laws on Creosote in Place of
Council Directive
94/60/EEC
12.
Conclusion
1. Introduction
Marketing
and use of Creosote and
preparations containing
Creosote as well as
creosote-treated wood has
been regulated by the
Directive 94/60/EC. The
provisions are based on the
classification for Creosote
laid down in Directive
94/69/EC which is an
adaptation of Directive
67/548/EEC on the
approximation of the laws,
regulations, and
administrative provisions
relating to the
classification, packaging and
labelling of dangerous
substances.
Classification
regarding carcinogenicity of
Creosote was based on the
content of benzo[a]pyrene
(BaP), because this PAH was
chosen as a marker substance
for the classification of
coal tar-derived mixtures.
According to Directive
94/60/EC classification of
such mixtures including
Creosote as carcinogens is
not necessary if the BaP
content is lower than 50 ppm.
Accordingly no restrictions
in sale or use exist for
Creosote containing less than
50 ppm BaP. Creosote
containing 50 - 500 ppm may
not be sold to consumers and
can be used in industrial
installations. Wood treated
with such Creosote can only
be used for professional and
industrial applications. Use
of such Creosote is
prohibited inside buildings,
in contact with plants or
food and on
playgrounds.
Several
Member States (NL, D, DK and
S) held the opinion that the
level of protection for human
health and the environment
was insufficient and
requested to maintain their
more restrictive national
legislations. However, except
The Netherlands, where a
particulate geographic
situation prevails, these
Member States failed to
submit any substantive
evidence that the level of
protection of the Community
Directive was
insufficient.
The
Commission and the Member
States made a joint
declaration that the
classification of Creosote
would be reviewed once the
results on an ongoing
carcinogenicity study of
Creosote would be known which
was carried out at that time
by the Fraunhofer Institute
(FhG) in Hannover/Germany.
The results of this study are
now available.
The dermal
carcinogenicity study and the
national justifications to
maintain the more strict
national regulations have
been submitted to the
Scientific Committee of
Toxicity, Ecotoxicity and the
Environment to advise the
Commission on the following
questions:
1. Is
there sufficient scientific
evidence to support the
opinion that there is a
cancer risk to consumers from
Creosote containing less than
50 ppm benzo[a]pyrene and/or
from wood treated with such
Creosote?
2. If such
a risk exists, can its
magnitude be estimated or
quantified?
2. Dermal
Carcinogenicity Study of
Two Coal Tar Products
(CTP),
CSTEE/98/10-Add
1:
In a 78
week study groups of 62 male
mice were treated dermally
with two different
preparations of coal tar oil
containing either 10 ppm or
300 ppm BaP (CTP1 and CPT2,
resp.) twice a week on the
clipped skin. CPT1 and CPT2
were administered biweekly
amounts of 1, 3 or 9 mg per
animal per treatment. The
resulting amounts of BaP are
given in Table 1 including
the amounts of BaP of the
positive control
group.
Table 1: Study design
of the dermal carcinogenicity
study in mice
using 2
coal tar oil preparations
(CTP1 and CTP2)
ID |
No. |
Sex |
Group Name |
Treatment twice a week with 25 m
l of a toluenic solution |
01 |
62 |
Male | Negative control (toluene)
(Solvent control) |
25 m
l toluene per treatment |
02 |
62 |
Male |
Positive
control B(a)P |
7.5
m
g B(a)P |
03 |
62 |
Male |
Low dose CTP 1 |
1 mg CTP 1
D 0.01
m
g B(a)P |
04 |
62 |
Male |
Medium dose
CTP |
3 mg CTP 1
D 0.03
m
g B(a)P |
05 |
62 |
Male | High dose CTP 1 | 9 mg CTP 1 D 0.09 m g B(a)P |
06 |
62 |
Male |
Low dose CTP 2 |
1 mg CTP 2
D 0.27
m
g B(a)P |
07 |
62 |
Male |
Medium dose
CTP 2 |
3 mg CTP 2
D 0.80
m
g B(a)P |
08 |
62 |
Male |
High dose CTP
2 |
9 mg CTP 2
D 2.4
m
g B(a)P |
The
following findings were
documented:
CPT1:
No skin
tumours were seen in the 1 mg
and 3 mg dose groups which
corresponded to the
application of 0.01 and 0.03
m
g BaP. At 3 mg (0.03
m
g BaP) 1 solitary squamous
cell carcinoma was observed,
2 solitary squamous cell
papillomas in the 9 mg (0.09
m
g BaP) group. However, those
incidences were not
statistically different from
the control group. Regarding
non-neoplastic
histopathological endpoints,
no statistically significant
deviations were found.
However, an increase in
ulcerated skin after 3 mg per
treatment and above was
observed, and decrease in
skin erythema at 9 mg. At
that dose mean life span was
not statistically significant
decreased from 494 days in
the untreated control group
to 447 days.
CPT2:
An
increased incidence in
squamous cell skin carcinoma
occurred after treatment with
3 mg (0,8
m
g BaP) and above, skin
papilloma starting at 1 mg
(0.27
m
g BaP) and multiple
papillomas at the highest
dose of 9 mg (2.4
m
g BaP). The mean life span
was significantly decreased
after treatment with 1 mg, 3
mg and 9 mg from 494 days in
the control to 444, 407, and
252 days,
respectively.
Overall,
the study showed a
dose-dependent increase of
malignant and non-malignant
skin tumours after CTP2
treatment and a
non-statistically significant
increase in total skin
tumours at the highest dose
after CTP1 treatment.
These
results agree with the
previously shown carcinogenic
potential of coal tar
extracts. The potency of the
different Creosote doses
applied to the skin
correlated directly with the
BaP contents, corroborating
the convention to relate the
carcinogenic potential of a
mixture to the marker
substance BaP. The highest
CTP2-dose of 9 mg per
application also supported
this relationship when the
reduced survival time of
these animals was taken with
consideration. (This becomes
evident when the incidence is
the reduced treatment
time.)
Moreover,
as compared to the amount of
BaP content in the Creosote
products, the tumour inducing
potency of the CTP2
formulation was about five
times higher than that
observed with BaP alone in
the positive control (Table
2). This observation has not
been further investigated. It
may either be due to the
presence of other
carcinogenic compounds in the
CTP or that the carcinogenic
effect of BaP has reached a
plateau at lower
concentrations which have not
been tested in the present
investigation.
Table 3: Potency of
CTP 2 related to BaP-contents
as compared to the potency of
the positive
BaP-control
| | | | | |
positive BaP
control |
mg CTP 2 |
0.1 |
0.3 |
1 |
3 |
9 x | |
m
g BaP |
0.03 |
0.08 |
0.27 |
0.8 |
2.4 |
7.4 |
Skin tumours |
1 |
3 |
9 |
23 |
20 |
47 |
Tumours
per
m
g BaP |
33 |
38 |
33 |
29 |
8 |
6 |
x ) Terminated
after 274 days because of
severe skin lesions
The T25
carcinogenic potency value
for BaP in this experiment
can be calculated to be 13
µg/kg bw/day
(CSTEE/98/10-Add. 16). The
CTP formulation tested here
had a five-fold higher
carcinogenic potency relative
to its BaP content (2.7 µg/kg
bw/day).
3. An Evaluation of the
Carcinogenicity of Coal-Tar
Derived Creosote,
CSTEE/98/10-Add. 2
(International Tar
Association):
The
International Tar Association
presented some information on
the composition of different
Creosote products. Those
produced at high temperature
have until recently contained
concentrations of BaP around
0.1 % (1000 ppm). It is,
however, claimed that most
Creosote products produced in
the EU today contain less
than 50 ppm BaP.
There is
also an interesting
comparison between the two
products tested in the
Fraunhofer Institute study
(CSTEE/98/10-Add.1). One of
these (CTP 1) contained 10ppm
BaP and the other (CTP 2) 271
ppm, a factor of 27 between
the two products. The
concentrations of
benzo(a)anthracene were 25
and 1190, respectively,
giving a factor of 48, and
another potent carcinogen,
dibenzo(a,h)anthracene, was
determined at 1 and 19.2 ppm,
respectively.
The paper
gives some comments on the
mouse skin painting study and
contrasts it with human
exposure situations. In the
mouse experiment the same
treated area is painted over
and over again, the mouse
does not wash the material
off and toluene is used as a
solvent in the painting
experiment. It was concluded
by the authors that it
describes a worst case
situation.
4. Foundation of the
Appeal against the
EC-directive on Creosote,
CSTEE/98/10-Add. 3
(Position of the
Netherlands):
In The
Netherlands approximately
10,000 kilometres of water
banks are protected with
creosote-treated timber. The
leaching of creosote from
this application is
considered one of the major
sources of pollution of
sediments with PAH.
In 1990
about 100,000 m
2 of wood has been
treated in The Netherlands
with approx. 9,000 tonnes of
Creosote, mainly applied for
bank protection, railway
sleepers, fencing and fruit
tree support. About 1,100
tonnes of coal tar varnish
has been applied by private
persons and farmers. Emission
of BaP to water, soil and air
from the use of coal tar oil
preparations in The
Netherlands have been
calculated.
The annual emissions during Creosote production and storage are 100 - 150 kg, in the usage phase 256 kg to soil, 212 to air and 133 kg to surface water. In the sediments of governmental and regional waters of more than 90 % of the samples the limit value of 0.05 mg BaP/kg d. s. is exceeded. About 80 % of this pollution is estimated to come from Creosote used for water bank protection. This is considered to be an unacceptable risk to the aquatic ecosystem, to higher species and possibly to man. The Netherlands therefore have not accepted the proposal of the 14th Amendment to the EC directive 76/769/EEC that Creosote for preserving wood for industrial installations may contain a maximum of 500 ppm BaP, and instead only allows a maximum of 50 ppm irrespective of the method of treatment. Moreover the Netherlands has restricted the use of Creosote and coal tar varnish regardless of the content of BaP. This is in contrast to the directive, which does not restrict the use of Creosote, containing less than 50 ppm BaP. The Dutch position is that this is expected to reduce exposure of the 3 high risk groups: the employees in Creosote plants, the neighbouring residents of Creosote production sites and children, who may get into contact with Creosote when playing on materials made of Creosote-treated wood by oral or skin contact.
Risk assessment of oral
exposure. The approach
has been to assess how much
Creosote from contaminated
soil in contact with
creosoted wood a child may
maximally ingest, given the
Dutch maximum permissible
daily dose of 12
m
g benzo(a)pyrene (B(a)P)/kg
bodyweight/day. Using this a
15 kg child may ingest
maximally 3.6 g of Creosote
with 50 ppm B(a)P. It is
judged that consuming such an
amount by a child is unlikely
for a child by way of
hand-mouth contact. Even if
this risk assessment is based
on B(a)P, and not Creosote
which in the skin-painting
experiments was 5 times as
potent as B(a)P (ref. the
Fraunhofer study,
CSTEE/98/10-Add. 1), this
judgement should be
valid.
Risk assessment of dermal
exposure Here one has used exposure data from an occupational study where assembly workers came into skin contact with creosoted wood. Exposure to children in contact with creosoted wood has been calculated simply by converting the occupational data on pyrene (a component of Creosote) by relating it to the smaller skin surface area, lower exposure periods and lower body weights. In addition, a direct conversion from pyrene to B(a)P was undertaken under the assumption that exposure to B(a)P was directly proportional to pyrene relative to their concentrations in Creosote. A calculation according to a dermal exposure scenario in children of 20 ng B(a)P/kg bw/day was compared to the Dutch permissible dermal dose limit in children of 1.6 ng/kg B(a)P/kg bw/day based on tumorigenicity data from mice. Since the exposure exceeded the limit, the risk was judged to be unacceptable. Note that there is a miscalculation in this report in that the dermal exposure should be 2 ng BaP/kg bw/day rather than 20 ng BaP/kg bw/day (see point 5, CSTEE/98/10-Add. 4).
The
exposure assessment may be
overestimated since the
exposure is given as amount
deposited on the skin, not
the amount taken up into the
body after dermal absorption.
There may be differences in
the degree of dermal
absorption of Creosote
between humans and mice.
Further, the exposure
assessment may be
overestimated since one has
assumed that exposure to
B(a)P is directly
proportional to that of
pyrene. On the other hand,
the risk assessment is
underestimated since it is
based upon B(a)P
carcinogenicity and not data
from the Fraunhofer study
with Creosote.
5. Study on the
Justification in Scientific
Terms of Allowing the
Netherlands to retain its
National Laws on Creosote
in Place of Council
Directive 94/60/EEC,
CSTEE/98/10-Add. 4
(Grimmer):
This is a
review of CSTEE/98/10-Add. 3
with critical comments to the
assessments and evaluations
therein. In the Appendix 3 of
the Dutch foundation of the
appeal (CSTEE/98/10-Add.3)
there is a miscalculation in
the estimation of the daily
exposure to BaP. The correct
amount should be 0.163 µg
rather than 1.63 µg. The
correct figure results in a
daily dose of 2 ng BaP/kg
bw/day. It gives some data on
the content of selected PAH
in Creosote and presents a
table of carcinogenic
potencies of various PAH
relative to B(a)P. However,
it does not specifically give
any new exposure data or risk
assessments of children
exposed to creosoted wood in
playgrounds. Therefore, this
report will not be further
commented upon.
6. Position of the
Government of the Federal
Republic of Germany,
CSTEE/98/10-Add. 5,
including
CSTEE/98/10-Add. 6
(MAK documentation):
In Germany
the designation Creosote is
used only for 9 different
liquid by-products of the
burning of coal or wood. The
regulations for these
formulations are based on the
content of BaP and on
contents of water-soluble
phenols. If the content of
phenols or BaP exceed 3% or
500 ppm, respectively, the
production and use are
prohibited. Formulations with
a BaP content between 50 and
500 ppm may only be used for
wood treatment in industrial
processes. Sale, including
that to private consumers, is
only permitted at a BaP
content up to 50 ppm. There
are also regulations for the
use and marketing of treated
wood products.
All other
tar oil-containing
formulations are not allowed
for sale to private consumers
irrespective of their BaP
content. For professional use
there are various
restrictions. Formulations
containing up to 5 ppm BaP
may only be used in closed
plants. Higher contents are
permitted for novel
impregnation together with a
final vacuum or re-heating.
50 to 500 ppm BaP
formulations are permitted
for the treatment of railway
sleepers and electricity
poles. Manufacture, use and
marketing of products
containing more than 500 ppm
is prohibited. Marketing and
use of the treated wood
products is also
regulated.
The more
strict regulations of tar oil
products have been justified
by the classification of BaP
and of PAH-containing
mixtures as animal
carcinogens by the German
MAK-Committee
(CSTEE/98/10-Add.6), the high
carcinogenic potency of the
PAH constituents and the
limited possibility to
quantify the carcinogenic
risk of human exposure.
Nevertheless a three times
per week skin contact of
children for 5 years with
wood treated with tar oil
containing 25% BaP has been
estimated to result in a 2%
lifetime risk of cancer
development. This risk
assessment has been based on
a dermal carcinogenicity
study in mice, which received
50
m
l of a solution containing 25
ppm and 50 ppm BaP three
times a week. The lower
concentration induced tumours
in 44%, the higher in 95% of
the animals.
7. Karlehagen
Epidemiology Study,
CSTEE/98/10-Add.
7:
Cancer
incidence was studied among
922 creosote-exposed
impregnators at 13 plants in
Sweden and Norway. The total
cancer incidence observed was
lower than expected, with 129
cases observed versus 137
expected. The excess of
cancer of the lip (5 observed
vs. 2.05 expected) is of
borderline statistical
significance (in Table 1,
footnote reports p=0.05
whereas 95 % confidence
interval in first line
includes unity). The excess
of non-melanoma skin cancer
was statistically
significant, and is
biologically plausible, being
concentrated in those working
10+ years and being related
to a cancer site which has
been previously suspected as
a target site of the same
agent. On the other hand, the
potential biases correctly
suggested by the authors
cannot be ruled out.
8. Evaluation of German
Exposure Estimates by ERM
(Environmental Resources
Management, London),
CSTEE/98/10-Add.
8:
The
evaluation of the German
position regarding exposure
and of additional data leads
to the conclusion that the
German population is not
directly exposed to unusually
high doses of Creosote
through products sold to
customers and through contact
with Creosote-treated timber,
nor is the German aquatic
environment exposed to
unusually high levels of PAHs
coming from Creosote-treated
wood.
While
little data were available
concerning the exposure of
German workers to Creosote,
it is considered likely that
exposure levels are
comparable to those in other
Member States. It is
considered unlikely that
German Workers are exposed to
unusually high levels of
Creosote in comparison to
other workers in other Member
States.
9. Human Health and
Environmental Concerns of
Creosote,
CSTEE/98/10-Add.9
(Danish Position):
The Danish
Authorities describe that
Creosote is not approved for
use in Denmark, although it
has been used for more than a
century. About 10,000 tonnes
of Creosote is, however,
produced in the country and
exported to Sweden, Norway
and Germany. These products
are claimed to contain less
than 50 ppm BaP.
A study of
Creosote composition in
impregnated poles after 40
years of use is described.
Substances with the lowest
boiling point showed the
highest migration and the
part of the poles above
ground had lost the largest
amounts. Creosote components
could only be detected in
soil in close contact with
the pole.
The
possibility of ground water
contamination is mentioned,
but the data on measured
concentrations of Creosote
components were restricted to
contaminated sites.
It is
claimed that the Danish
climate will decrease the
importance of degradation,
both photolytic and
microbial, as compared to
other countries in the
EU.
10. Report to the
Commission of the European
Union by SORGO consultant,
CSTEE/98/10-Add. 10
(Position of Denmark):
P. M.
Sorgo has evaluated the
contribution from the Danish
Authorities (CSTEE/98/10-Add.
9). In summary, he found that
the Danish population is not
exposed to unusually high
doses of PAH from the use of
Creosote, neither from
treated wood or via ground
water consumption. These
conclusions were, however,
based on the present
situation when no Creosote is
used in the country.
11. Study on the
Justification in Scientific
Terms of Allowing Sweden to
retain its National Laws on
Creosote in Place of
Council Directive
94/60/EEC,
CSTEE/98/10-Add.
11:
This is a very detailed and transparent report of high quality. In contrast to CSTEE/98/10-Add. 3, one has here assessed exposure in children by calculating the amount absorbed into the body based on skin absorption rate data for pyrene from a human coal-tar ointment study. The calculated uptake of B(a)P was 0.85 ng/kg bw/day, and thus substantially lower than the calculated exposure in CSTEE/98/10-Add. 3 (20 ng/kg bw/day). A large part of this difference is due to the fact that here the absorbed dose, and not the dose applied on the skin, was calculated. This report has used a permissible dose of 4.8 ng/kg bw/day (and not 1.6 ng/kg bw/day as in CSTEE/98/10-Add. 3) since the exposure period was set to 2 hours a day for six months (and not 3 hours a day for a whole year). It was judged that the cancer risk to children from direct exposure to Creosote from contact with creosote-treated wood will not be unacceptable (disproportionally high), since the uptake was less than the permissible dose for this scenario.
The
exposure assessment scenario
involving the private use of
creosote-treated wood and
treatment of untreated wood
with Creosote for
construction purposes
provided an uptake of B(a)P
of 47 ng/kg bw/day. This was
correlated to the Dutch
permissible daily dose for
B(a)P via skin exposure for
an adult member of the
general public of 2.1
m
g/kg bw/day (recalculated
with an exposure period of 8
hours per day for two weeks
every year). Also this
exposure was judged not to be
unacceptably
(disproportionally)
high.
In this
case the exposure assessment
relies on a number of
assumptions, which may or may
not hold true (these are
clearly presented in the
text). In addition, the
exposure may be
underestimated since the
calculations have used mean
absorption rates for pyrene,
and not maximum values (12 vs
23 pmol/cm²/hr). On the other
hand, the exposure assessment
may be overestimated since
one has assumed that
absorption of B(a)P is
directly proportional to that
of pyrene. In contrast, the
risk assessment is
underestimated since it is
based upon B(a)P
carcinogenicity and not data
from the Fraunhofer study
with Creosote.
12. Conclusion
Creosote
is a coal tar product, which
contains varying amounts of
PAHs and other mutagenic and
carcinogenic substances. Coal
tar products including
Creosote are classified as
potential human carcinogens
(EU: Category 2, IARC: 2A).
This is mainly based on
several positive skin
painting studies in mice as
well as some suggestive
epidemiological evidence in
humans. Due to the genotoxic
potential of PAHs including
BaP and other components of
coal tar the carcinogenic
potential cannot be
considered thresholded. As a
consequence the carcinogenic
risk of exposure is
considered linearly
dose-dependent so that each
exposure is also associated
with a certain risk even at
low doses.
The
carcinogenic potential of
coal tar preparations has
been reaffirmed by a skin
painting study performed by
the Fraunhofer Institute. The
CSTEE concludes that this is
a well-designed study which
clearly indicates a linear
dose response relation to the
BaP content of the
administered substances. Both
preparations (CPT1 and CPT2)
have a five-fold higher
potency to induce skin
tumours than BaP, presumably
due to the presence of other
substances than BaP in
Creosote. It can be inferred
from the Fraunhofer study
that Creosote containing 50
ppm BaP would induce a
significant incidence of skin
cancer in mice.
Data to
fully evaluate the relevance
of effects seen in a mouse
skin painting study for human
exposure situations are
insufficient. Species
dependent sensitivity of
dermal exposure to the
carcinogenic actions of
Creosote will be affected by
morphology and physiology of
the skin, by metabolic
activation and inactivation
in the skin and by repair
processes. Moreover the
precision of the human
exposure estimates presented
in the different reports is
debatable. On the basis of
the available information, a
scientifically justified
assessment of carcinogenic
risk e.g. for the dermal
exposure of children playing
on wood treated with Creosote
is therefore
difficult.
Exposure
of children from dermal
contact with creosote-treated
wood has been estimated from
either occupational studies
of pyrene or a coal-tar
ointment study, and
recalculated with respect to
BaP. These two estimates are
fairly similar (2 vs 0.85 ng
BaP/kg bw/day). The CSTEE
concludes that these
estimates are quite
uncertain, but that they give
an indication of the possible
dimension of the actual
exposure. Annual intakes of
BaP from food has been
estimated to be in the order
of 0.3 - 1.6 mg (Fritz) 1971;
Jacob and Grimmer 1996;
Santodonato et al. 1979;
Strubelt 1986). This would
result in daily exposures of
12 - 63 ng/kg bw for a person
weighing 70 kg.
Extrapolating
skin carcinogenicity data
from mice to the human
situation also entails a
number of uncertainties
leading to difficulties in
directly using cancer potency
data from mice to assess
cancer risk in humans.
However, based on linear
extrapolation of the potency
of Creosote revealed in the
Fraunhofer study, the
lifetime risk from the
calculated exposure estimates
of approximately 1 ng BaP/kg
bw/day would be in the order
of 10
-4. Such a risk
level gives clear reason for
concern.
The Scientific
Committee of Toxicity,
Ecotoxicity and the
Environment concludes the
following:
1. Given
the genotoxicity of BaP and
the outcome of the Fraunhofer
skin painting study, there is
sufficient scientific
evidence to support the
opinion that there is a
cancer risk to consumers from
Creosote containing less than
50 ppm BaP and/or from wood
treated with such
Creosote.
BaP is a
good indicator for the
carcinogenic hazard of the
Creosote preparation tested,
since there was a linear
relationship between cancer
incidence and BaP dose.
However, the cancer potency
of the Creosote preparation
was 5-fold higher than judged
from its BaP content.
2. On the
basis of the available
information, even taking into
account the considerable
uncertainties in assessing
the risks for children coming
into contact with
Creosote-treated wood, the
magnitude of the risk gives
clear reasons for concern.
However, the highest
estimated exposure is some
6-30 times lower than the
oral exposure of the adult
population to BaP in
food.
In order
to get a better estimate of
the exposure situation, one
would have to perform a
real-life, mass-balance study
in exposed children. In
addition to being very
complicated and resource
intensive, to conduct such a
study would raise ethical
questions.
Annex
List of documents made
available to the Scientific
Committee on Toxicity,
Ecotoxicity and the
Environment via its
Secretariat to help it
reach the opinion requested
by the services of the
Commission on the
subject:
'Cancer risk to
consumers from Creosote
containing less than 50
ppm benzo-[a]-pyrene
and/or from wood treated
with such Creosote and
estimation of respective
magnitude'
CSTEE/98/10
Hazardous
properties of
Creosote.
Note from Mr. P. Ortùn
(Director III/C) to Mr. B.
Carsin (Director XXIV/B)
dated 20/3/98 - Ref.
005846.
CSTEE/98/10 - Add. 1
Dermal
Carcinogenicity Study of two
Coal Tar Products (CTP) by
Chronic Epicutaneous
Application in Male CD-1 Mice
(78 weeks)
Final report made by the
Fraunhofer Institute of
Toxicology and Aerosol
Research (Hannover).
CSTEE/98/10 - Add. 2
An
Evaluation of the
Carcinogenicity of Coal-Tar
derived Creosote
Submitted by the
International Tar
Association (UK) -
29/12/1997.
CSTEE/98/10 - Add. 3
Foundation
of the appeal against the
EC-directive on
creosote
Made by bkh consulting
engineers on request of the
Dutch Ministry of Housing,
Spatial Planning and
Environment - Delft (NL)
11/7/1995.
CSTEE/98/10 - Add. 4
Study on
the Justification in
Scientific Terms of Allowing
the Netherlands to retain its
National Laws on Creosote in
Place of Council Directive
94/60/EEC
Made by Prof. Dr.G.
Grimmer(Biochemisches
Institüt für
Umweltcarcinogene -
Germany) on request of the
European Commission
(contract no.
ETD/95/84066).
CSTEE/98/10 - Add. 5
Report of
the Government of the Federal
Republic of Germany of 19
June 1995 concerning
Directive 94/60/EC of the EP
and of the Council of
20/12/94 on the 14
th amendment to
Directive 76/769/EEC for
alignment of the legal and
administrative regulations of
the Member States for
restricting the marketing and
use of certain hazardous
substances and formulations
(OJ No. L 365 of 31/12/94, p.
1).
Submitted by the German
Authorities in support of
their request under Art.
100a (4).
CSTEE/98/10 - Add. 6
A report
from theGerman MAK Commission
on the suitability of
Benzo[a]pyrene as a marker
substance "Polycyclische
Aromatische
Kohlenwasserstoffe,
krebserzeugende (PAH)" and
its translation into English
"Polycyclic aromatic
hydrocarbons, carcinogenic
(PAH)".
CSTEE/98/10 - Add. 7
Cancer
incidence among
creosote-exposed
workers
From the Scand. J. Work
Environ. Health - 1992.
CSTEE/98/10 - Add. 8
Study on
the Scientific Evaluation of
the German Request for a
Derogation from the
Provisions of Council
Directive 94/60/EC concerning
creosote (April 1996).
Made by ERM Consultants
on request of the European
Commission (contract no.
ETD/95/84081).
CSTEE/98/10 - Add. 9
A report
"Human Health and
Environmental Concerns of
Creosote" (5/12/1995)
Submitted by the Danish
Authorities in support of
their request under Art.
100a (4) - 5/12/1995.
CSTEE/98/10 - Add.
10
Study on
the Justification in
Scientific Terms of Allowing
Danmark to retain its
National Laws on Creosote in
Place of Council Directive
94/60/EEC
Made by Dr. Sorgo
(Consultant) on request of
the European Commission
(contract no. ETD/96/84094)
- 20/11/1996 - and an
additional letter from Dr.
Sorgo.
CSTEE/98/10 - Add.
11
Study on
the Justification in
Scientific Terms of Allowing
Sweden to retain its National
Laws on Creosote in Place of
Council Directive
94/60/EEC
Made by WS ATKINS
Consultants on request of
the European Commission
(contract no.
ETD/96/500069) - August
1997.
CSTEE/98/10 - Add.
12
Creosote -
draft outline report for
CSTEE information
CSTEE/98/10 - Add.
13
Evaluation
of a Dermal Carcinogenicity
Study with Mice with Two
Different Creosotes.
Report
from Fraunhofer-Institute of
Toxicology and Aerosol
Research (Hannover) - May
1998.
Document
transmitted by Mr. P. Buigues
(DG III).
CSTEE/98/10 - Add.
14
T25: A
Simplified Carcinogenic
Potency Index: Description of
the System and Study of
Correlations between
Carcinogenic Potency and
Species/Site Specificity and
Mutagenicity.
Report
from E. Dybing - January
1997.
CSTEE/98/10 - Add.
15
Potency
considerations regarding
Creosote.
Report
from Prof. Jansson -
4/8/1998.
CSTEE/98/10 - Add.
16
Creosote -
Comments from Erik
Dybing.
Report
from E. Dybing -
31/8/1998.
CSTEE/98/10 - Add.
17
Fritz, W.
(1971) Umfang und Quellen der
Kontamination unserer
Lebensmittel mit
krebserzeugenden
Kohlenwasserstoffen,
Ernähruungsforsch, XVI, 4,
547-557.
CSTEE/98/10 - Add.
18
Jacob, J.
und Grimmer, G. (1996)
Metabolism and excretion of
polycyclic aromatic
hydrocarbons in rat and in
human. Centr. Eur. J. publ.
Hlth 4, Suppl. p.
33-39.
CSTEE/98/10 - Add.
19
Santodonato, J.,
Basu, D. und Howard, P.H.
(1979) Multimedia human
exposure and carcinogenic
risk assessment for
environmental PAH,
Polynuclear Aromatic
Hydrocarbons, Chemistry and
Biological Effects. Bjorseth,
A. and Dennis A. J. (Eds.),
Battelle Press, Columbus,
Ohio, 435-454.
CSTEE/98/10 - Add.
20
Strubelt, O.
(1986) Über das Viorkommem und
die Bedeutung von Karzinogen in
der menschlichen Umwelt. Dt.
Apoth. Z. 126, 1977.